GHK-Cu

A copper peptide investigated in relation to skin, tissue repair, the extracellular matrix and inflammatory regulation

Overview

GHK-Cu is formed by combining a short tripeptide, GHK, with a divalent copper ion. The GHK sequence is made up of three amino acids — glycine, histidine and lysine — and once bound to copper, the complex is referred to in the literature as glycyl-L-histidyl-L-lysine-Cu2+ and, in dermatology and cosmetics, as Copper Tripeptide-1 [1,2]. GHK was first identified in the 1970s as a constituent of human plasma with biological activity on cells; its chemical sequence was subsequently established, and it was shown to bind copper with comparatively high affinity [1,2]. Scientific interest stems from its pairing of two significant biological elements: a short peptide with signalling activity, and copper, a trace element involved in enzymes linked to collagen, elastin, antioxidants and tissue repair [3,6]. While most GHK-Cu research concerns skin and connective tissue, it extends well beyond cosmetics. The peptide has been studied in relation to wound healing, fibroblast activity, collagen and glycosaminoglycan synthesis, regulation of inflammation, extracellular-matrix remodelling and the expression of tissue-repair genes [4-8].

Biological Mechanism

The extracellular matrix is a network of collagen, elastin, proteoglycans, glycosaminoglycans and other proteins that surrounds cells and underpins tissue structure. In skin and connective tissue, matrix quality matters every bit as much as the quantity of collagen. Proper healing depends on the orderly breakdown of damaged tissue, cell migration, assembly of new matrix and reorganisation of collagen fibres. In fibroblast cultures, GHK-Cu was found to raise collagen synthesis at low concentrations without a matching rise in cell number [4], a result pointing to a regulatory effect on the cell rather than simple general stimulation of the culture. A further study showed that GHK-Cu increases synthesis of glycosaminoglycans — mainly dermatan sulfate and heparan sulfate, both important to the structure and function of the extracellular matrix [5]. Subsequent reviews suggest that GHK-Cu also works by balancing matrix construction and breakdown, having been linked to changes in metalloproteinase activity, metalloproteinase inhibitors, the fibroblast response, and pathways related to inflammation and oxidative stress [6,8]. Its activity is thus not confined to 'promoting collagen' but relates to wider tissue remodelling.

Research Evidence

An animal study in the Journal of Clinical Investigation examined the effect of GHK-Cu on experimental wounds in rats. The authors reported that it promoted connective-tissue accumulation at the wound site together with changes in collagen and matrix measures [7] — findings consistent with a possible role for GHK-Cu in the structural repair phase of tissue. A 2012 study in Genome Medicine looked at GHK from the wider perspective of gene expression. The researchers identified a gene-expression signature linked to lung-tissue destruction in emphysema and showed that GHK emerged as a molecule capable of reversing some of these expression patterns in cellular and bioinformatic models [8]. The study does not demonstrate a treatment for lung disease, but it does indicate that GHK may influence biological programmes connected with connective tissue, inflammation and repair. Small clinical studies and dermatological preparations also exist in the skin field, but GHK-Cu itself must be distinguished from other copper complexes and from combined cosmetic formulations. A favourable result with one preparation does not show that every product containing Copper Tripeptide-1 behaves in the same way or with the same potency.

Biological Activity Versus Cosmetic Outcome

A key difficulty in interpreting GHK-Cu research lies in moving from cellular measures to clinical ones. A study showing increased collagen synthesis in fibroblasts does not necessarily mean the same effect will occur in living skin, which has an epidermal barrier, blood flow, enzymatic degradation, immune responses and considerable variation between formulations [4,9]. The strength of the evidence should therefore be read in context: culture studies illuminate mechanism, animal studies indicate healing potential, and small clinical studies test the practical outcome of a specific preparation. The difference between free copper and a peptide-copper complex is another important factor. Free copper can take part in undesirable oxidation reactions, whereas binding to a peptide may alter its availability and how it is delivered to cells [3]. GHK-Cu is therefore not the equivalent of a copper supplement or general copper exposure; its biological activity depends on the structure of the complex, its stability, concentration, chemical environment and ability to reach the target tissue. In the genetic study of emphysema, GHK emerged as a molecule able to influence gene-expression signatures associated with lung-tissue destruction, cytoskeletal organisation and collagen remodelling [8]. This widens interest in the peptide beyond the skin, but it also underlines the limits of translation: altered gene expression in cell culture is not a proven treatment for a chronic disease. The research value of GHK-Cu lies in the model it offers for understanding the relationship between short peptides, trace metals, the extracellular matrix and cellular repair programmes. From a dermatological perspective, the important question is not simply whether GHK-Cu 'increases collagen', but whether it improves tissue quality over time. Proper remodelling encompasses collagen formation, breakdown of damaged collagen, fibre organisation, regulation of inflammation and support for glycosaminoglycans. A 2015 review suggests that GHK is involved in several of these axes simultaneously, including metalloproteinases and their inhibitors [6]. Describing it as a peptide associated with matrix repair is therefore more accurate than reducing it to a narrow cosmetic label.

Safety & Regulation

The safety context for GHK-Cu depends heavily on route of exposure: a topical skin preparation is not comparable to systemic exposure. Evaluation of dermal formulations covers pH, stability, permeability, carriers and other ingredients, not just the peptide. A pre-formulation study found GHK-Cu to be susceptible to degradation under certain conditions, making stability and manufacturing quality an important part of its assessment [9]. The FDA notes that compounded injectable preparations containing GHK-Cu may raise concerns about immunogenicity, aggregation, peptide-related impurities and inadequate characterisation of the active substance, and that human data for assessing safety via such routes are limited [10]. The distinction between topical dermatological research and systemic exposure is therefore central.

Translational Limits & Quality Measures

Any assessment of preparations containing GHK-Cu must also take formulation into account. A peptide that is stable in a test tube will not necessarily remain stable in a finished product, and development studies have found GHK-Cu to be sensitive to pH, oxidation and hydrolytic degradation [9]. In skin, it must also cross the stratum corneum, an especially effective biological barrier. The same molecule may therefore perform impressively in the laboratory yet yield variable results across different preparations. A further, deeper consideration is the difference between young, ageing and damaged skin. Ageing tissue shows changes in fibroblasts, declining collagen quality, higher levels of degradation enzymes, reduced water content and a shift in low-grade chronic inflammation. GHK-Cu has attracted study because it may influence several of these features at once [6,8]. Demonstrating a consistent clinical effect, however, would require studies measuring not only outward appearance but also dermal thickness, collagen organisation, elasticity, barrier function and safety over time.

Summary

GHK-Cu ranks among the most thoroughly studied copper tripeptides in relation to skin and connective tissue. The evidence indicates possible involvement in collagen, glycosaminoglycans, fibroblasts and the extracellular matrix [4-8], but most of this knowledge derives from cell studies, animal studies and small clinical studies, and extrapolation to systemic uses is not adequately established [9,10]. The material is supplied for laboratory research use only.

Selected Research Sources

1. Pickart L., Thaler M.M. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology, 1973. PMID: 4349963
2. Schlesinger D.H., Pickart L., Thaler M.M. Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia, 1977. PMID: 858356
3. Pickart L. et al. Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature, 1980. PMID: 7453802
4. Maquart F.X. et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988. PMID: 3169264
5. Wegrowski Y. et al. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sciences, 1992. PMID: 1522753
6. Pickart L., Vasquez-Soltero J.M., Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMID: 26236730
7. Maquart F.X. et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID: 8227353
8. Campbell J.D. et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine, 2012. NIH.gov
9. Badenhorst T. et al. Physicochemical characterization of GHK-Cu for dermal delivery. Pharmaceutical Development and Technology, 2016. PMID: 25384620
10. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Entry for GHK-Cu. FDA.gov